Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cognition Therapeutics, Inc.
< Previous
1
2
Next >
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD
October 31, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD
October 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD
October 23, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)
October 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference
October 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia
October 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
September 03, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
August 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
August 08, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
August 05, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
July 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
July 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
May 21, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
May 07, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
April 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
April 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
April 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
April 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
March 15, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
March 14, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
March 11, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
March 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
February 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
February 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics CEO Issues Letter to Shareholders
January 04, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
November 16, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
November 15, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
November 07, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Tickers
CGTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.